Page last updated: 2024-12-08

l 737126

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: structure given in first source; an inhibitor of HIV-1 reverse transcriptase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID454844
CHEMBL ID283950
SCHEMBL ID2344264
MeSH IDM0300129

Synonyms (22)

Synonym
AC-13609
5cl3phso2-2indolconh2
5-chloro-3-(phenylsulfonyl)-2-indolecarboxamide
bdbm2278
3-(benzenesulfonyl)-5-chloro-1h-indole-2-carboxamide
l-737,126
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide
148472-83-7
csic
rs1202
CHEMBL283950
l-737126
5-chloro-3-phenylsulfonylindole-2-carboxamide
KHJNUJLYIHQWQI-UHFFFAOYSA-N
3-phenylsulfonyl-5-chloroindole-2-carboxamide
5-chloro-3-(phenylsulfonyl)-1h-indole-2-carboxamide
3-benzenesulfonyl-5-chloroindole-2-carboxamide
l 737126
AKOS015961287
SCHEMBL2344264
DTXSID50163992
FT-0754617

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel."( 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Balani, SK; Ciccarone, TM; Condra, JH; Emini, EA; Goldman, ME; Greenlee, WJ; Kauffman, LR; MacTough, SC; Rooney, CS; Williams, TM, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel."( 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Balani, SK; Ciccarone, TM; Condra, JH; Emini, EA; Goldman, ME; Greenlee, WJ; Kauffman, LR; MacTough, SC; Rooney, CS; Williams, TM, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.89580.00060.91418.3200AID1795381; AID1795395
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)1.30300.00011.076810.0000AID200151; AID200152; AID313898; AID313899
Protease Human immunodeficiency virus 1IC50 (µMol)0.08750.00010.22487.3200AID200169; AID200170; AID200171; AID80893
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID200170Inhibition single mutant of HIV-1 RT (K103 N)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID246786Concentration required to reduce the amount of p24 by 90% in C8166 cells infected with an efavirenz-resistant strain EFVR2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID106775Inhibition of cell culture in MT-4 cells1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID80893Activity to inhibit mutant HIV-1 rRT activity in Y181C2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID313897Inhibition of HIV NL43 recombinant reverse transcriptase by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).
AID44823Anti-HIV activity to reduce the amount of p24 in C8166 cells infected with efavirenz resistance strain carrying mutations K103R2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID200151Activity to inhibit HIV-1 Reverse transcriptase activity in K103N2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID246359Protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID104802In vitro cytotoxicity against mock infected MT-4 cells.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID313899Inhibition of HIV NL43 recombinant reverse transcriptase Y181C mutant by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).
AID44818Anti-HIV activity to reduce the amount of p24 in C8166 cells infected with efavirenz resistance strain2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID106942Anti-HIV activity protecting MT-4 cells from HIV-1 induced cytopathogenicity2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID106747Cytotoxicity, reducing the vaiability of mock-infected cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID44798In vitro concentration required to reduce the amount of p24 by 90% in WTIIIB infected C8166 cells2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID200169Inhibition of HIV-1 RT using rC-dG as template1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID246779Concentration required to reduce the amount of p24 by 90% in wtIIIB-HIV-1-infected C8166 cells2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID392513Antiviral activity against HIV12009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID105325Inhibition of Efavirenz resistant HIV-1 (Y181C) induced cytopathicity in MT-4 cells.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID246153Concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID200171Inhibition single mutant of HIV-1 RT (Y181C)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID105324Inhibition of Efavirenz resistant HIV-1 (K103N-Y181C) induced cytopathicity in MT-4 cells.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID44797In vitro reduction of p24 by 90% in Efavirenz resistant HIV-1 (K103R, V179D, P225H) infected C8166 cells.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID200152Activity to inhibit HIV-1 Reverse transcriptase activity in WT IIIB2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID265460Antiviral activity against HIV12006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID313898Inhibition of HIV NL43 recombinant reverse transcriptase K103N mutant by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).
AID701102Antiviral activity against wild type HIV12012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
AID105326Inhibition of HIV-1 (IIIB) induced cytopathicity in MT-4 cells.2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID246203Concentration required to achieve 50% protection of infected MT-4 cells from Y181C-HIV-1 strain2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID232055Selectivity index (Ratio of CC50/EC50).2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID232923Selectivity ratio of CC50/EC502003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID1705189Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID44824Anti-HIV activity to reduce the amount of p24 in WT IIIB infected C8166 cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID1795381HIV-1 RT Assay from Article 10.1021/jm00061a022: \\5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.\\1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID1795395HIV-1 RT Assay from Article 10.1021/jm0211063: \\Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.\\2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (20.00)18.2507
2000's6 (60.00)29.6817
2010's1 (10.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]